
Quarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Cash Flow 2011-2026 | ADMP
Annual Cash Flow Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-25.9 M | -37.8 M | -20.9 M | -19.9 M | -32.7 M | -15.1 M | -21.2 M | - | -6.78 M | -2.56 M | -3.35 M | -4.31 M |
Depreciation & Amortization |
1.48 M | 1.44 M | 2.33 M | 2.94 M | 3.1 M | 3.06 M | 2.53 M | 990 K | 296 K | - | - | 14.6 K |
Accounts Payables |
7.94 M | 3.75 M | 3.49 M | 4.27 M | 4.17 M | 2.92 M | 2.15 M | 498 K | 787 K | 2.43 M | 2.02 M | - |
Accounts Receivables |
1.05 M | 816 K | 1.09 M | 1.88 M | 1.16 M | 830 K | 805 K | - | - | - | - | - |
Total Inventories |
1.24 M | 419 K | 3.12 M | 2.06 M | 3.28 M | 1.82 M | 942 K | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -1.55 M | - | -24.4 M | -16.9 M | -6.99 M | - | -31.1 M | -21.3 M | -4.54 M | - | -15.5 M | -9.38 M | -4.24 M | - | -16.9 M | -12.7 M | -8.27 M | - | -20.4 M | -12.4 M | -7.95 M | - | -9.89 M | -6.98 M | -3.51 M | - | -17.9 M | - | - | - | - | - | - | - | - | -2.66 M | - | - | - | -1.98 M | - | - | -2.54 M | -1.93 M | - | - | -2.7 M | -1.99 M | - |
Depreciation & Amortization |
67 K | 109 K | - | 399 K | 368 K | 344 K | - | 375 K | 369 K | 328 K | - | 897 K | 878 K | 917 K | - | 816 K | 712 K | 842 K | - | 2.32 M | 1.54 M | 771 K | - | 2.32 M | 1.56 M | 783 K | - | 1.75 M | 147 K | 248 K | - | 743 K | 495 K | 248 K | - | 888 K | 296 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
9.97 M | 9.78 M | 7.94 M | 5.3 M | 4.52 M | 4.89 M | 3.75 M | 2.45 M | 3.01 M | 4.04 M | 1.78 M | 1.78 M | 3.49 M | 3.49 M | 4.27 M | 4.27 M | 4.27 M | 4.27 M | 4.17 M | 4.17 M | 4.17 M | 4.17 M | 2.92 M | 2.92 M | 2.92 M | 2.92 M | 2.15 M | 2.15 M | 2.15 M | 2.15 M | 498 K | 498 K | 498 K | 498 K | 787 K | 787 K | 787 K | 787 K | 1.71 M | 2.34 M | 2.08 M | 2.43 M | 1.94 M | 1.84 M | 1.82 M | 2.02 M | 1.73 M | 1.63 M | 1.27 M | 1.26 M |
Accounts Receivables |
- | - | 1.05 M | 1.31 M | - | 1.52 M | 816 K | 735 K | 1.31 M | 1.19 M | 242 K | 242 K | 1.09 M | 1.09 M | 1.88 M | 1.88 M | 1.88 M | 1.88 M | 1.16 M | 1.16 M | 1.16 M | 1.16 M | 830 K | 830 K | 830 K | 830 K | 805 K | 805 K | 805 K | 805 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
663 K | 664 K | 1.24 M | 1.09 M | 440 K | 32 K | 419 K | - | 2.17 M | 2.56 M | 1.23 M | 1.23 M | 3.12 M | 3.12 M | 2.06 M | 2.06 M | 2.06 M | 2.06 M | 3.28 M | 3.28 M | 3.28 M | 3.28 M | 1.82 M | 1.82 M | 1.82 M | 1.82 M | 942 K | 942 K | 942 K | 942 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Adamis Pharmaceuticals Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Drug manufacturers sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
$ 1.14 | -4.62 % | $ 123 M | ||
|
Cronos Group
CRON
|
$ 2.56 | 1.24 % | $ 1.35 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 4.74 | 1.94 % | $ 66.6 M | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
$ 11.08 | 0.82 % | $ 567 M | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
$ 5.05 | -2.88 % | $ 313 M | ||
|
Harrow Health
HROW
|
$ 47.49 | -0.86 % | $ 1.55 B | ||
|
China Pharma Holdings
CPHI
|
$ 1.25 | - | $ 21.8 M | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
$ 1.62 | 0.62 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
$ 6.75 | -3.3 % | $ 2.46 B | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | ||
|
Sundial Growers
SNDL
|
$ 1.58 | -2.17 % | $ 3.37 M | ||
|
Organogenesis Holdings
ORGO
|
$ 3.64 | -3.96 % | $ 479 M | ||
|
Pacira BioSciences
PCRX
|
$ 19.43 | 1.38 % | $ 899 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.51 | 0.14 % | $ 2.05 B | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
$ 15.06 | 0.2 % | $ 2.07 B | ||
|
Aurora Cannabis
ACB
|
$ 4.14 | -2.13 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
$ 1.22 | 27.44 % | $ 28.5 M | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 3.33 | 1.06 % | $ 4.13 M | ||
|
Relmada Therapeutics
RLMD
|
$ 3.93 | 5.01 % | $ 118 M | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
$ 12.04 | 4.88 % | $ 855 M | ||
|
Tilray
TLRY
|
$ 8.74 | -7.62 % | $ 5.4 B | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
$ 5.59 | 2.19 % | $ 228 M | ||
|
SCYNEXIS
SCYX
|
$ 0.65 | -0.68 % | $ 31.1 M | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | ||
|
Veru
VERU
|
$ 2.53 | -5.95 % | $ 341 M | ||
|
TherapeuticsMD
TXMD
|
$ 2.55 | 14.39 % | $ 26.6 M | ||
|
Viatris
VTRS
|
$ 12.66 | -1.59 % | $ 15.3 B | ||
|
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | ||
|
cbdMD
YCBD
|
$ 0.83 | -9.94 % | $ 3.58 M |